亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers

克拉斯 生物利用度 癌症 口服活性 药理学 医学 结直肠癌 化学 口服 内科学
作者
Fei Xiao,K. Wang,Xinjuan Wang,H. Li,Zhilong Hu,Xiaoming Ren,Wei Huang,Teng Feng,Lili Yao,Jing Lin,Chunlai Li,Zhuanzhuan Zhang,Liufeng Mei,Xiaotian Zhu,Wei-Zhu Zhong,Zhi Xie
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
卷期号:: OF1-OF14
标识
DOI:10.1158/1535-7163.mct-24-0049
摘要

Abstract KRAS is the most frequently dysregulated oncogene with a high prevalence in non–small cell lung cancer, colorectal cancer, and pancreatic cancer. FDA-approved sotorasib and adagrasib provide breakthrough therapies for patients with cancer with KRASG12C mutation. However, there is still high unmet medical need for new agents targeting broader KRAS-driven tumors. An emerging and promising opportunity is to develop a pan KRAS inhibitor by suppressing the upstream protein of Son of Sevenless 1 (SOS1). SOS1 is a key activator of KRAS and facilitates the conversion of GDP-bound KRAS state to GTP-bound KRAS state. Binding to its catalytic domain, small-molecule SOS1 inhibitor has demonstrated the ability to suppress KRAS activation and cancer cell proliferation. RGT-018, a potent and selective SOS1 inhibitor, was identified with optimal drug-like properties. In vitro, RGT-018 blocked the interaction of KRAS:SOS1 with single-digit nanomoles per liter potency and was highly selective against SOS2. RGT-018 inhibited KRAS signaling and the proliferation of a broad spectrum of KRAS-driven cancer cells as a single agent in vitro. Further enhanced antiproliferation activity was observed when RGT-018 was combined with MEK, KRASG12C, EGFR, or CDK4/6 inhibitors. Oral administration of RGT-018 inhibited tumor growth and suppressed KRAS signaling in tumor xenografts in vivo. Combinations with MEK or KRASG12C inhibitors led to significant tumor regression. Furthermore, RGT-018 overcame the resistance to the approved KRASG12C inhibitors caused by clinically acquired KRAS mutations either as a single agent or in combination. RGT-018 displayed promising pharmacological properties for combination with targeted agents to treat a broader KRAS-driven patient population.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
清脆冥幽完成签到,获得积分20
11秒前
FashionBoy应助lbjcp3采纳,获得30
20秒前
33秒前
44秒前
小巫发布了新的文献求助10
47秒前
47秒前
48秒前
zhangxr发布了新的文献求助10
50秒前
54秒前
桐桐应助科研通管家采纳,获得30
55秒前
Simon应助科研通管家采纳,获得10
55秒前
爆米花应助科研通管家采纳,获得10
55秒前
lbjcp3发布了新的文献求助30
58秒前
打打应助zhangxr采纳,获得10
59秒前
1分钟前
阿杜阿杜发布了新的文献求助10
1分钟前
1分钟前
阿杜阿杜完成签到,获得积分20
1分钟前
asd1576562308完成签到 ,获得积分10
2分钟前
张振希完成签到,获得积分10
2分钟前
烟花应助科研通管家采纳,获得10
2分钟前
情怀应助白萝卜采纳,获得10
2分钟前
3分钟前
3分钟前
温暖的盼山完成签到 ,获得积分10
3分钟前
张振希发布了新的文献求助10
3分钟前
3分钟前
王桑完成签到 ,获得积分10
3分钟前
kyfbrahha完成签到 ,获得积分10
3分钟前
情怀应助lbjcp3采纳,获得10
4分钟前
4分钟前
4分钟前
4分钟前
唐唐完成签到 ,获得积分10
4分钟前
4分钟前
4分钟前
杰帅发布了新的文献求助10
4分钟前
lbjcp3发布了新的文献求助10
4分钟前
上官若男应助科研通管家采纳,获得10
4分钟前
星辰大海应助科研通管家采纳,获得10
4分钟前
高分求助中
The Oxford Handbook of Social Cognition (Second Edition, 2024) 1050
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Handbook of Qualitative Cross-Cultural Research Methods 600
Chen Hansheng: China’s Last Romantic Revolutionary 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3139573
求助须知:如何正确求助?哪些是违规求助? 2790430
关于积分的说明 7795287
捐赠科研通 2446905
什么是DOI,文献DOI怎么找? 1301487
科研通“疑难数据库(出版商)”最低求助积分说明 626238
版权声明 601146